Experimental drug auxora tested in critical COVID-19 lung patients
NCT ID NCT04661540
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This small Phase 2 trial tested an experimental drug called Auxora in 10 patients with critical COVID-19 pneumonia who were on ventilators. The goal was to see how the drug affected immune cells in the lungs and to check its safety. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Auxora (CM4620-IE)
- What this could lead to
- If successful, Auxora could help control severe immune reactions in critical COVID-19 pneumonia, potentially improving outcomes for ventilated patients.
- What could go wrong
- This was a very small, early-phase trial (only 10 participants) that was terminated early, so results are limited. The drug may not show clear benefit or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI could outsmart bacteria: a smarter way to choose antibiotics?
- Breathing technique may outperform spirometry for smog pneumonia recovery
- A gentle touch against coughs and colds: could manual therapy shorten respiratory illness?
- Can a smart oxygen device shorten hospital stays for pneumonia?
- Could everyday supplements shield your lungs?
- Can a simple inhaled combo keep pneumonia patients off ventilators?